Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks. By Nina Agrawal Jennifer Le’s doctor ticked ...

The American College of Rheumatology (ACR) has released a summary of a guideline with updated recommendations for the treatment of systemic lupus erythematosus (SLE). The previous guideline for ...

Background This study aimed to investigate the clinical characteristics, outcomes, and risk factors of patients with a rare but fatal manifestation of systemic lupus erythematosus (SLE), diffusive ...

Lupus nephritis frequently recurs after kidney transplantation, and it may be clinically quiescent, investigators report. Among 112 first-time kidney transplant recipients with lupus nephritis history ...

Session ID: 2025-07-05:c4ea86776358cff0718e05ac Player Element ID: vjs_video_3 ...

Complications from lupus may involve the heart, lungs, kidneys and brain, leaving 89% of affected individuals unable to work full-time, according to the Lupus Foundation of America.

Class 2 lupus nephritis was the most common disease state, occurring in approximately 40% of each group. It was characterized by a mesangioproliferative pattern of glomerular injury.

Medicare covers treatment that you may need following a lupus diagnosis. Depending on your age, it may also cover tests and consultations leading up to diagnosis. Out-of-pocket costs will apply ...

Lupus is unpredictable and can be life-altering, but knowledge is power. Recognizing the warning signs, advocating for early diagnosis and following a treatment plan can make a significant difference.

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the treatment of lupus nephritis. Obinutuzumab is a ...

Objective : To report the experience in three Brazilian institutions with the use of rituximab in patients with different clinical forms of lupus erythematosus systemic in activity. Methods : The ...